Renaissance RX Announces New Chief Financial Officer Thierry Amat

NEW ORLEANS, Oct. 29, 2014 /PRNewswire/ -- Thierry Amat joined Renaissance RX this month as its executive vice president and chief financial officer (CFO). With experience in mergers and acquisitions and more than 20 years in pharmaceuticals, Amat will be a valuable asset to the fast-growing company.

Renaissance RX began in 2012 with five employees and today employs more than 800 team members across the United States. The laboratory specializes in pharmacogenetic testing, which identifies how patients respond to specific medications based on their genetic makeup. The test results Renaissance RX provides allow physicians to prescribe the precise medications and dosages that are best for individuals.

"We are thrilled to have Thierry join our team to head up our financial department," said Dr. Tarun Jolly, founder and CEO of Renaissance RX. "With the unprecedented growth we've seen, Thierry's unique expertise will help us scale up and grow our capacity to explore new sciences and technologies."

Amat has been an executive at Fortune 500 corporations as well as small and mid-sized Private Equity-backed entrepreneurial firms. For the past seven years he has worked in the Clinical Research Organizations and Healthcare Services arenas.

Prior to joining Renaissance RX, Amat was the senior vice-president and CFO of Remedi SeniorCare, a long-term care pharmacy provider that ranks as one of the nation's largest institutional pharmacy companies. There he created a customer profitability model that supported sales and business development efforts and improved ROIC on new and existing pharmacies.

As CFO of the drug design and discovery company Aptuit between 2008 and 2012, Amat increased cash collections by $40 million with an aggressive receivables program; and he created a new international structure that resulted in more than $4.5 million in tax savings. Later he identified, negotiated, and merged the GSK R&D Center in Verona, Italy into Aptuit in less than six months with full team retention and strong cash flow benefits. In 2012 he managed the sale of Aptuit's Clinical Trial Supplies Business for 9.5 times EBITDA.

Between 2005 and 2008, Amat was the CFO of SODEXHO INC., a global leader in the hospitality industry with $16 billion in revenue with more than 45 percent generated in North America.

Prior to SODEXHO INC., Amat spent 19 years in a number of capacities at Sanofi, a diversified global healthcare company engaged in the research, development, manufacture and marketing of healthcare products. Its business includes pharmaceuticals, vaccines, and animal health. In 2012, the company's net sales were €35 billion.

Amat earned his BS in Accounting from Reims Management School in Rheims, France and his MBA in Corporate Finance from Northeastern University in Boston, MA. In 2005 Thierry joined a group of Executive MBAs from the Wharton School and climbed to the base camp of Everest in the Khumbu region of Nepal.

About Renaissance RX
Personalized medicine is transforming the world by allowing physicians to develop treatment plans based on information that is unique to each patient, including health history, environment, and genetic makeup. Renaissance RX is pioneering this new era of health care, providing the tools that make personalized medicine possible. The laboratory offers pharmacogenetic testing and Advanced Toxicology, which produce the data that allow for a high level of individualized treatment. The lab's science builds upon decades of research in toxicology, genetics, molecular sciences, and pharmaceuticals to make an unprecedented level of precision health care possible.

For more information, visit RenRX.com.

Photo - http://photos.prnewswire.com/prnh/20141029/155241

Logo - http://photos.prnewswire.com/prnh/20141029/155230LOGO

SOURCE Renaissance RX

Related Links

http://www.RenRX.com